Alivus Lifesciences Base Case Target Achieved

Authored By HDFC SKY | Last Modified: Mar 18, 2026 12:55 PM IST

Open Free Demat Account

In our pick of the week report dated Jan 25, 2026 on Alivus Lifesciences, we had recommended to buy in the band of Rs 882-899 and add on dips to Rs 799-808 band for base case target of Rs 981 and bull case target of Rs 1077 over the next 4 quarters.

Today, the stock touched high of Rs 984, thereby hitting base case target of Rs 981, yielding a return of 10.2%.

Disclaimer

At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Disclaimer

At HDFC SKY*, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations.
HDFC SKY from HDFC Securities, one of most trusted trading platforms in India, has been recognized with the *Next-Gen Digi Content Awards 2025-26.

Markets